ArticleJAMA network open2022
Geographic and Racial Disparities in Access to Chimeric Antigen Receptor-T Cells and Bispecific Antibodies Trials for Multiple Myeloma.
Article in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.
- T-Cell Engagers TargetingInternational journal of molecular sciences · 2026Pooled it
- Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States.Blood cancer journal · 2026Trial
- Article
- Geospatial Access to CAR-T Clinical Trials for Non-Hodgkin Lymphoma for Persons With HIV.JAMA network open · 2026Article
- The European CAR-T map-Current status and future directions to improve access to CAR T-cell therapy for hematologic malignancies.HemaSphere · 2026Article
- MajesTEC-3: Redefining what's possible in multiple myeloma.Clinical hematology international · 2026Article
- Inequalities in CAR T-cell therapy access for US patients with relapsed/refractory DLBCL: a SEER-Medicare data analysis.Blood advances · 2025Article
- Multiple myeloma care, treatment patterns, and treatment durations in academic and community care settings.Future oncology (London, England) · 2025Observational
- Toward equitable regenerative medicine: a health equity research framework for emerging regenerative treatments.Regenerative medicine · 2025Review
- Disparities in Clinical Trial Enrollment- Focus on CAR-T and Bispecific Antibody Therapies.Current hematologic malignancy reports · 2024Review
- Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.Blood advances · 2024Article
- Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.Blood cancer journal · 2024Review
- Functional cure and long-term survival in multiple myeloma: how to challenge the previously impossible.Haematologica · 2024Review
- Diversity, Equity, and Inclusion in Multiple Myeloma: A Call to Action.Journal of the advanced practitioner in oncology · 2024Review
- Trends in volumes and survival after hematopoietic cell transplantation in racial/ethnic minorities.Blood advances · 2024Observational
- Article
- Impact of race and social determinants of health on outcomes in patients with aggressive B-cell NHL treated with CAR-T therapy.Blood advances · 2024Article
- "They don't care to study it": Trust, race, and health care experiences among patient-caregiver dyads with multiple myeloma.Cancer medicine · 2024Article
- Perspectives on the Treatment of Multiple Myeloma.The oncologist · 2024Review
- Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.Blood advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: The use of chimeric antigen receptor-T cell (CAR-T) therapy and bispecific antibodies in multiple myeloma is expanding, with encouraging early results. It is unknown if the current geographic distribution of CAR-T therapy and bispecific antibodies in multiple myeloma allows access for patients in need, especially for Black populations, which have a higher incidence of multiple myeloma. Objective: To investigate if the current geographic distribution of CAR-T cell therapy and bispecific antibodies for multiple myeloma allows equitable access for Black patients with multiple myeloma. Design, Setting, and Participants: This cross-sectional study of data from CAR-T therapy and bispecific antibodies multiple myeloma clinical trials for all available studies listed in ClinicalTrials.gov until January 31, 2022. Only studies with 1 or more open sites in the US were analyzed. Data were analyzed February 2022. Results: A total of 162 clinical trials were found, and 69 analyzed-7896 participants were either enrolled or expected to enroll, with 4386 participants (55.5%) enrolled or to be enrolled in CAR-T therapies clinical trials. The vast majority of clinical trials (66 [96%]) were sponsored by industry, and there were 140 clinical trials sites. The mean number of sites per trial was 8.1 (7.8 for CAR-T trials [range, 1-30 trials] vs 8.7 for bispecific antibodies [range, 1-26 trials]). Only 35.9% of Black patients lived in a county with an open trial. For the 10 states with the highest proportion of Black residents (ranging from 18.6% to 41.4%), 6 of those states (60%) had no (3 states) or less than 3 clinical trial openings (3 states) for either a CAR-T or bispecific antibody study. Conclusions and Relevance: In this cross-sectional study, we found that the geographic distribution of clinical trials for CAR-T and bispecific antibodies may contribute to disparities in access to the most advanced clinical trials for new multiple myeloma therapies. Since most of the ongoing trials were sponsored by industry, regulating the distribution of clinical trial sites may reduce these inequities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.